Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02241187 · ClinicalTrials.gov registry record · NA

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

A NA study of Pancreatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
NA
Development phase
2
Enrollment target
1
Study location

NCT02241187: Completed NA study of Pancreatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02241187 is a NA study of Pancreatic Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02241187, a NA study of Pancreatic Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
NA
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects of PEGPH20 on tumors will be studied.

Primary Outcome

administration on resectable pancreatic adenocarcinoma tumors. DW- and DCE-MRI and distribution of cetuximab will be used to study tumor permeability to small and larger molecules, respectively. Resected tumors will be carefully studied for evidence of stromal degradation.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Cetuximab
  • OTHER blood draws
  • DRUG PEGPH20
  • DEVICE DW & DCE-MRI

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2014-09-12
Est. Completion 2016-09-13
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT02241187 record still lists

NCT02241187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.

NCT02241187 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02241187 about?

NCT02241187 is a clinical study titled "Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection". This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects o...

What is the current status of trial NCT02241187?

This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2014-09-12. Estimated completion is 2016-09-13.

What conditions does trial NCT02241187 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT02241187?

The interventions under investigation include: Cetuximab (DRUG), blood draws (OTHER), PEGPH20 (DRUG), DW & DCE-MRI (DEVICE).

Who is sponsoring clinical trial NCT02241187?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02241187 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02241187's enrollment target sits among peer trials

2 278th of 278 the lowest of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02241187, the US trial registry maintained by the National Library of Medicine. NCT02241187 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.